title: Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital.
abstract: BACKGROUND
  Imipenem/cilastatin is an antibacterial agent of the carbapenem class of β-lactams that is known to have an extremely wide spectrum of activity against Gram-positive, Gram-negative, aerobic, anaerobic, and even multidrug-resistant strains. The objective of this study was to evaluate the appropriate use of imipenem/cilastatin in a local tertiary care hospital. The study assessed the indication both empirically and after the culture results were available, the dose and dose adjustment in renal failure, as well as the incidence of seizure in hospitalized patients receiving imipenem/cilastatin.
  
  
  METHODS
  This observational study was conducted in a tertiary care hospital over a 3-month period. The treatment of 100 patients with imipenem/cilastatin was evaluated both empirically and after culture results were available. Analysis of the appropriateness of imipenem/cilastatin indication, dose, and monitoring of seizure frequency was based on the package insert, updated published guidelines, and clinical judgment.
  
  
  RESULTS
  Patients from internal medicine and intensive care units comprised approximately 50% of the population in the study. The patients received imipenem/cilastatin mainly for urinary tract infections (27%) or for sepsis of an unknown focus (22%). The use of imipenem/cilastatin empirically was appropriate in 97.2% (n=69/71) of the cases, and its use postculture in 86% of the cases. There were 29% of the patients who were not started on imipenem/cilastatin empirically. Four patients out of the 29 patients (13.8%) who were not started on imipenem/cilastatin empirically inappropriately received imipenem/cilastatin post-culture results. Thirty-three patients (33%) were not dosed appropriately, 30 of whom had renal impairment and creatinine clearance fluctuations. Only one patient developed a seizure while on imipenem/cilastatin.
  
  
  CONCLUSIONS
  The prescription of imipenem/cilastatin at our setting was mostly appropriate to what is recommended in the guidelines and the literature, although a few cases could have been managed better. Dosage adjustment, however, was not as appropriate, mainly in patients who did not have a stable creatinine clearance.
authors.affiliation: Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, Byblos, Lebanon.
authors.forename: Wissam K
authors.initials: WK
authors.lastname: Kabbara
authors.affiliation: Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, Byblos, Lebanon.
authors.forename: George T
authors.initials: GT
authors.lastname: Nawas
authors.affiliation: Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, Byblos, Lebanon.
authors.forename: Wijdan H
authors.initials: WH
authors.lastname: Ramadan
keywords: cilastatin; dose; imipenem; indication; seizure
references.citation: Clin Infect Dis. 2006 Mar 1;42(5):657-68
references.pmid: 16447111
references.citation: Antimicrob Agents Chemother. 2009 May;53(5):1983-6
references.pmid: 19273670
references.citation: Arch Intern Med. 2006 May 8;166(9):955-64
references.pmid: 16682568
references.citation: Clin Infect Dis. 2011 Feb 15;52(4):e56-93
references.pmid: 21258094
references.citation: J Antimicrob Chemother. 2009 Sep;64 Suppl 1:i3-10
references.pmid: 19675017
references.citation: Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2009 Apr;21(4):234-6
references.pmid: 19374793
references.citation: Clin Infect Dis. 2011 Mar 1;52(5):e103-20
references.pmid: 21292654
references.citation: Clin Infect Dis. 2010 Jan 15;50(2):133-64
references.pmid: 20034345
references.citation: J Antimicrob Chemother. 2000 Sep;46(3):501-8
references.pmid: 10980183
references.citation: J R Soc Med. 2002;95 Suppl 41:22-6
references.pmid: 12216271
references.citation: Am J Med. 1988 May;84(5):911-8
references.pmid: 3284342
references.citation: Drugs. 1987 Mar;33(3):183-241
references.pmid: 3552595
references.citation: Antimicrob Agents Chemother. 2004 Dec;48(12):4606-10
references.pmid: 15561832
references.citation: Am J Infect Control. 2004 Dec;32(8):470-85
references.pmid: 15573054
references.citation: Clin Infect Dis. 2014 Jul 15;59(2):e10-52
references.pmid: 24973422
references.citation: MMWR Morb Mortal Wkly Rep. 2004 Nov 19;53(45):1063-6
references.pmid: 15549020
references.citation: Clin Infect Dis. 2012 Jun;54(12):1679-84
references.pmid: 22619239
references.citation: Clin Infect Dis. 2011 May;52 Suppl 5:S397-428
references.pmid: 21474585
references.citation: Science. 2009 Sep 11;325(5946):1345-6
references.pmid: 19745137
references.citation: Clin Pharm. 1986 Sep;5(9):719-36
references.pmid: 3530614
references.citation: Clin Pharm. 1984 Sep-Oct;3(5):536-40
references.pmid: 6593143
references.citation: Rev Chilena Infectol. 2006 Dec;23(4):307-15
references.pmid: 17186077
references.citation: Arch Intern Med. 1989 Aug;149(8):1881-3
references.pmid: 2669668
references.citation: Clin Infect Dis. 2005 Sep 15;41(6):848-54
references.pmid: 16107985
references.citation: Crit Care. 2008;12 Suppl 4:S4
references.pmid: 18495061
references.citation: BMC Pulm Med. 2010 Aug 26;10:45
references.pmid: 20796312
references.citation: Drugs. 1992 Sep;44(3):408-44
references.pmid: 1382937
references.citation: DICP. 1991 Apr;25(4):351-4
references.pmid: 1926901
references.citation: Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S170-3
references.pmid: 11524715
references.citation: Crit Care Med. 2013 Feb;41(2):580-637
references.pmid: 23353941